查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953526

口服抗凝血劑市場－全球產業規模、佔有率、趨勢、機會及預測（按藥物類型、適應症、最終用戶、地區和競爭格局分類，2021-2031年）

Direct Oral Anticoagulants Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Indication, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球口服抗凝血劑（DOAC）市場預計將從 2025 年的 333.6 億美元成長到 2031 年的 519.2 億美元，複合年成長率為 7.65%。

這些藥物作為特效治療藥物，能夠選擇性地抑制特定的凝血蛋白（尤其是凝血酶或Xa因子），從而抑制血栓形成。市場快速擴張的主要促進因素是全球人口老化以及血栓栓塞性疾病（如深層靜脈栓塞症和心房顫動）盛行率的不斷上升。此外，由於患者和醫護人員都更傾向於選擇這些新型藥物，因為它們具有可預測的藥物動力學特性，且監測需求更低，因此臨床實踐正在逐步淘汰傳統的維生素K拮抗劑。根據美國心臟協會（AHA）2024年的數據，心血管疾病將佔全球死亡人數的三分之一左右，凸顯了對有效預防中風和血栓症管理策略的巨大且持續的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 333.6億美元
市場規模：2031年 519.2億美元
複合年成長率：2026-2031年 7.65%
成長最快的細分市場 心房顫動（心房顫動）
最大的市場 北美洲

然而，這些強效抗凝血​​藥物帶來的顯著出血風險，阻礙了市場上漲趨勢的發展。儘管逆轉劑已經研發成功，但其高昂的實施成本以及在新興國家供應有限，往往阻礙了其廣泛應用。這項經濟障礙對這些強效抗凝血​​療法的普及構成了重大挑戰。

市場促進因素

靜脈血栓栓塞症和心房顫動的盛行率不斷上升，尤其是在全球人口老化背景下，是推動市場成長的主要因素。隨著預期壽命的延長，這些血栓栓塞性疾病的發生率顯著增加，因此亟需有效的長期抗凝血策略來降低全身性栓塞和中風的風險。這種人口結構的變化正在穩步擴大需要長期治療性介入的患者群體。美國疾病管制與預防中心 (CDC) 在 2024 年 5 月的一份報告中強調了這些疾病日益加重的負擔，並預測到 2030 年，美國將有 1,210 萬人患有心房顫動。這項預測凸顯了迫切需要可及且有效的治療方法來應對這群不斷擴大且脆弱的患者所帶來的風險。

同時，與傳統維生素K拮抗劑相比，這些治療方法具有更優的臨床療效和更方便的使用方式，正推動市場發展。醫療服務提供者和患者越來越傾向於選擇這些新型藥物，因為它們具有可預測的藥物動力學特性，並且無需進行繁瑣的常規國際標準化比值（INR）監測。這種臨床偏好的廣泛轉變體現在該類領先藥物的商業性成功上。例如，2024年2月，百時美施貴寶公司報告其旗艦口服抗凝血劑的全球銷售額達到122億美元，顯示市場對這些先進治療方案的需求強勁。世界卒中組織估計，到2024年，全球每年將發生超過1,200萬例中風，因此，這些藥物提供的安全性保障對於有效的預防性抗凝血治療仍然至關重要。

市場挑戰

全球新型口服抗凝血治療方法（DOAC）市場的成長受到其固有嚴重出血風險的顯著阻礙。尤其是顱內出血和消化道出血等不可控出血的可能性，使得臨床醫生在為高風險患者群體開立此類藥物時猶豫不決。此外，安全管理帶來的經濟負擔也加劇了這種謹慎態度。儘管有逆轉劑，但其高昂的購買成本使得許多醫療系統難以負擔。因此，在成本受限的環境下，醫療機構往往為了避免處理併發症帶來的經濟風險而放棄使用這些先進藥物。

近期數據顯示，抗凝血藥物的安全性問題給醫療服務帶來了沉重負擔，凸顯了這項安全隱患的重要性。根據美國疾病管制與預防中心（CDC）2024年的數據，抗凝血藥物是導致患者因藥物不良反應而就診急診室的主要原因，約佔此類緊急應變的21%。如此高頻率的藥物相關急診需要耗費大量醫療資源進行住院治療，直接抵消了新型口服抗凝血藥物（DOAC）的臨床效益。臨床安全風險和高成本持續限制DOAC的市場滲透率，尤其是在開發中國家。

市場趨勢

隨著專利到期，非專利DOAC的上市正在從根本上改變競爭格局。尤其是在歐洲，隨著主要品牌藥的專利保護期近期結束，這種結構性轉變正在加速從高利潤品牌藥向性價比更高的生物等效替代藥的轉變，顯著影響著老牌製藥巨頭的收入來源。學名藥監管核准的增加導致市場價格普遍下降。這看似矛盾，一方面擴大了對價格敏感地區患者的用藥途徑，另一方面卻挑戰了品牌藥的商業性優勢。此趨勢的財務影響已顯現：2024年2月，百時美施貴寶公司公佈其旗艦抗凝血藥物艾樂妥（Eliquis）的國際銷售額為9.75億美元（經外匯調整後下降3%）。這主要是由於平均淨售價下降以及學名藥在多個歐洲國家的市場佔有率受到侵蝕。

同時，新一代因子XI抑制劑的臨床開發代表著一項突破性進展，旨在將止血與血栓症管理分開。與目前出血風險顯著的新型口服抗凝血藥物（DOAC）不同，這些新型藥物旨在預防病理性血栓形成，同時保留損傷修復所需的凝血機制。這項以安全性為導向的創新滿足了高風險族群（包括需要同時接受抗血小板治療的患者）對安全抗凝血藥物的龐大需求。近期試驗結果支持了此類藥物的臨床前景。 2024年11月，Anthos Therapeutics公司報告稱，在接受抗血小板治療的患者中，新型因子XI抑制劑avelacrimab與標準治療藥物利Rivaroxaban相比，出血事件顯著減少了67%，凸顯了其重新定義安全標準的潛力。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球口服抗凝血劑（DOAC）市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依藥物類型（Xa因子抑制劑、直接凝血酶抑制劑）
    • 依適應症（心房顫動（AF）、深層靜脈栓塞症（DVT）、肺動脈栓塞（PE）、中風預防、其他）
    • 依最終使用者（醫院/診所、門診手術中心、居家醫療機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美口服抗凝血劑（DOAC）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲口服抗凝血劑（DOAC）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區口服抗凝血劑（DOAC）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲口服抗凝血劑（DOACs）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲口服抗凝血劑（DOAC）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

13. 全球直介面服抗凝血劑（DOAC）市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Pfizer Inc.
  • Sanofi
  • Zhejiang Huahai Pharmaceutical Co. Ltd.
  • Janssen Global Services, LLC
  • Aspen Pharmacare Holdings Limited
  • Astellas Pharma Inc.
  • Lupin Pharmaceutical, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27562

The Global Direct Oral Anticoagulants (DOACs) Market is projected to expand from USD 33.36 Billion in 2025 to USD 51.92 Billion by 2031, reflecting a CAGR of 7.65%. These pharmaceuticals serve as specialized therapeutic agents that selectively inhibit specific coagulation proteins, notably thrombin or Factor Xa, to mitigate blood clot formation. Rapid market expansion is primarily fueled by an aging global population and the increasing prevalence of thromboembolic disorders such as deep vein thrombosis and atrial fibrillation. Furthermore, the clinical landscape is shifting away from traditional Vitamin K antagonists, as both patients and healthcare providers prefer the predictable pharmacokinetics and reduced monitoring necessities associated with these newer options. Data from the American Heart Association in 2024 indicates that cardiovascular disease was responsible for roughly one in three deaths worldwide, emphasizing the critical and continuous demand for effective stroke prevention and thrombosis management strategies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 33.36 Billion
Market Size 2031USD 51.92 Billion
CAGR 2026-20317.65%
Fastest Growing SegmentAtrial Fibrillation (AF)
Largest MarketNorth America

However, the market's upward trajectory encounters a significant obstacle regarding the risk of major bleeding events linked to these potent medications. Although reversal agents have been developed, their high acquisition costs and limited availability in emerging economies often discourage widespread implementation. This economic barrier presents a substantial challenge to the universal adoption of these sophisticated anticoagulant therapies.

Market Driver

The escalating prevalence of venous thromboembolism and atrial fibrillation, particularly within an aging global demographic, serves as the primary catalyst for market growth. As life expectancy increases, the incidence of these thromboembolic conditions rises markedly, creating a need for effective long-term anticoagulation strategies to lower the risk of systemic embolism and stroke. This demographic shift generates a consistent and growing patient pool requiring chronic therapeutic intervention. Highlighting the increasing burden of these conditions, the Centers for Disease Control and Prevention projected in a May 2024 report that 12.1 million individuals in the United States will suffer from atrial fibrillation by 2030. This forecast underscores the urgent necessity for accessible and effective treatments to address the risks associated with this expanding vulnerable population.

Concurrently, the market is driven by the superior clinical profile and convenience these therapies offer compared to traditional Vitamin K antagonists. Healthcare providers and patients are increasingly prioritizing these newer agents because they provide predictable pharmacokinetics and eliminate the burdensome requirement for routine International Normalized Ratio monitoring. This broad shift in clinical preference is quantitatively demonstrated by the commercial success of leading drugs in this class. For instance, Bristol Myers Squibb reported in February 2024 that its flagship oral anticoagulant generated worldwide revenues of $12.2 billion, signaling robust demand for these advanced therapeutic options. Given that the World Stroke Organization estimated in 2024 that over 12 million strokes occur globally each year, the safety assurance provided by these medications remains critical for effective preventative anticoagulation.

Market Challenge

The growth of the Global DOACs Market is significantly hindered by the inherent risk of major bleeding events associated with these powerful therapies. The potential for uncontrolled hemorrhaging, specifically intracranial and gastrointestinal bleeding, creates considerable hesitation among clinicians when prescribing for high-risk patient groups. This caution is compounded by the economic burden of safety management; although reversal agents are available, their prohibitive acquisition costs often render them inaccessible within many healthcare systems. Consequently, providers in cost-constrained environments frequently forgo these advanced agents to avoid the financial risks associated with managing potential complications.

The magnitude of this safety concern is underscored by recent data highlighting the strain on healthcare services. According to the Centers for Disease Control and Prevention in 2024, anticoagulants were the leading cause of emergency department visits for adverse drug events, accounting for approximately 21% of these critical encounters. This high frequency of medication-related emergencies necessitates resource-intensive hospitalizations, directly offsetting the perceived clinical advantages of DOACs. The convergence of clinical safety risks and the high cost of emergency reversal therapies continues to restrict market penetration, particularly in developing economies.

Market Trends

The introduction of generic DOAC formulations following patent expirations is fundamentally reshaping the competitive landscape, particularly in European markets where exclusivity periods for major brands have recently concluded. This structural shift is forcing a transition from high-margin branded therapies to cost-effective bioequivalent alternatives, significantly impacting the revenue streams of established pharmaceutical leaders. As regulatory bodies increasingly approve these generic options, the market is experiencing widespread price erosion, which paradoxically expands patient access in cost-sensitive regions while challenging the commercial dominance of originator drugs. The financial implication of this trend is already visible; Bristol Myers Squibb reported in February 2024 that international revenues for its leading anticoagulant Eliquis were $975 million, representing a 3% decrease adjusted for foreign exchange, primarily driven by lower average net selling prices and generic erosion in several European countries.

Simultaneously, the clinical development of next-generation Factor XI inhibitors represents a pivotal advancement aimed at decoupling hemostasis from thrombosis management. Unlike current DOACs that carry a risk of major bleeding, these novel agents are designed to prevent pathologic thrombus formation while sparing the coagulation mechanisms necessary for injury repair. This safety-centric innovation addresses the critical unmet need for anticoagulants that can be safely administered to high-risk populations, such as those requiring concomitant antiplatelet therapy. The clinical promise of this class is substantiated by recent trial results; in November 2024, Anthos Therapeutics reported that the novel Factor XI inhibitor abelacimab demonstrated a substantial 67% reduction in bleeding events for patients on antiplatelet therapy compared to the standard-of-care rivaroxaban, highlighting its potential to redefine safety standards.

Key Market Players

  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Pfizer Inc.
  • Sanofi
  • Zhejiang Huahai Pharmaceutical Co. Ltd.
  • Janssen Global Services, LLC
  • Aspen Pharmacare Holdings Limited
  • Astellas Pharma Inc.
  • Lupin Pharmaceutical, Inc.

Report Scope

In this report, the Global Direct Oral Anticoagulants (DOACs) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Direct Oral Anticoagulants (DOACs) Market, By Drug Type

  • Factor Xa Inhibitors
  • Direct Thrombin Inhibitors

Direct Oral Anticoagulants (DOACs) Market, By Indication

  • Atrial Fibrillation (AF)
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Stroke Prevention
  • Others

Direct Oral Anticoagulants (DOACs) Market, By End User

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Others

Direct Oral Anticoagulants (DOACs) Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Direct Oral Anticoagulants (DOACs) Market.

Available Customizations:

Global Direct Oral Anticoagulants (DOACs) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Direct Oral Anticoagulants (DOACs) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Factor Xa Inhibitors, Direct Thrombin Inhibitors)
    • 5.2.2. By Indication (Atrial Fibrillation (AF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke Prevention, Others)
    • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Direct Oral Anticoagulants (DOACs) Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Indication
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Direct Oral Anticoagulants (DOACs) Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Direct Oral Anticoagulants (DOACs) Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Direct Oral Anticoagulants (DOACs) Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By End User

7. Europe Direct Oral Anticoagulants (DOACs) Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Indication
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Direct Oral Anticoagulants (DOACs) Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By End User
    • 7.3.2. France Direct Oral Anticoagulants (DOACs) Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Direct Oral Anticoagulants (DOACs) Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Direct Oral Anticoagulants (DOACs) Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Direct Oral Anticoagulants (DOACs) Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By End User

8. Asia Pacific Direct Oral Anticoagulants (DOACs) Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Indication
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Direct Oral Anticoagulants (DOACs) Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By End User
    • 8.3.2. India Direct Oral Anticoagulants (DOACs) Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Direct Oral Anticoagulants (DOACs) Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Direct Oral Anticoagulants (DOACs) Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Direct Oral Anticoagulants (DOACs) Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By End User

9. Middle East & Africa Direct Oral Anticoagulants (DOACs) Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Indication
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Direct Oral Anticoagulants (DOACs) Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Direct Oral Anticoagulants (DOACs) Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Direct Oral Anticoagulants (DOACs) Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By End User

10. South America Direct Oral Anticoagulants (DOACs) Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Indication
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Direct Oral Anticoagulants (DOACs) Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Direct Oral Anticoagulants (DOACs) Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Direct Oral Anticoagulants (DOACs) Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Direct Oral Anticoagulants (DOACs) Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bayer AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Boehringer Ingelheim International GmbH
  • 15.3. Bristol Myers Squibb Company
  • 15.4. Pfizer Inc.
  • 15.5. Sanofi
  • 15.6. Zhejiang Huahai Pharmaceutical Co. Ltd.
  • 15.7. Janssen Global Services, LLC
  • 15.8. Aspen Pharmacare Holdings Limited
  • 15.9. Astellas Pharma Inc.
  • 15.10. Lupin Pharmaceutical, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer